![Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study - The Lancet Oncology Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/d9703228-fc3a-4361-8574-cece79e56c05/gr1.jpg)
Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study - The Lancet Oncology
![Breast Cancer Basics: Hormonal Therapy (How To Decide If You Should You Take It For 5 Or 10 Years) – IOE Program by Dr. Brian Lawenda Breast Cancer Basics: Hormonal Therapy (How To Decide If You Should You Take It For 5 Or 10 Years) – IOE Program by Dr. Brian Lawenda](https://integrativeoncology-essentials.com/wp-content/uploads/2019/03/Screen-Shot-2019-03-28-at-11.39.28-AM-519x1024.png)
Breast Cancer Basics: Hormonal Therapy (How To Decide If You Should You Take It For 5 Or 10 Years) – IOE Program by Dr. Brian Lawenda
![It's not time to abandon routine screening mammography in average-risk women in their 40s | MDedge ObGyn It's not time to abandon routine screening mammography in average-risk women in their 40s | MDedge ObGyn](https://cdn.mdedge.com/files/s3fs-public/obgm03210-pearlman_web_t1.jpg)
It's not time to abandon routine screening mammography in average-risk women in their 40s | MDedge ObGyn
External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement | PLOS ONE
![Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial | npj Breast Cancer Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-021-00288-8/MediaObjects/41523_2021_288_Fig1_HTML.png)
Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial | npj Breast Cancer
![A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints - The Lancet Oncology A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints - The Lancet Oncology](https://www.thelancet.com/cms/attachment/fe468876-c413-4818-b918-0f871d688eda/gr1_lrg.jpg)
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints - The Lancet Oncology
![PDF) An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation PDF) An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation](https://i1.rgstatic.net/publication/317157626_An_updated_PREDICT_breast_cancer_prognostication_and_treatment_benefit_prediction_model_with_independent_validation/links/59728b0b0f7e9b401694486e/largepreview.png)
PDF) An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation
![Prediction models in cancer care - Vickers - 2011 - CA: A Cancer Journal for Clinicians - Wiley Online Library Prediction models in cancer care - Vickers - 2011 - CA: A Cancer Journal for Clinicians - Wiley Online Library](https://acsjournals.onlinelibrary.wiley.com/cms/asset/57900c48-ea3e-4a94-83a6-3ca44db35abd/mfig005.jpg)
Prediction models in cancer care - Vickers - 2011 - CA: A Cancer Journal for Clinicians - Wiley Online Library
![Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update | Journal of Clinical Oncology Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2022/jco.2022.40.issue-16/jco.22.00069/20230316/images/abs-fig.jpg)
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update | Journal of Clinical Oncology
![Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study - Modern Pathology Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study - Modern Pathology](https://mp.uscap.org/cms/asset/9ae860b0-dcac-4b6d-9b51-565655ad9366/gr1.jpg)
Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study - Modern Pathology
![JPM | Free Full-Text | Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report JPM | Free Full-Text | Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report](https://www.mdpi.com/jpm/jpm-02-00071/article_deploy/html/images/jpm-02-00071-g001.png)
JPM | Free Full-Text | Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report
![PDF) External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement | Anne Vincent-salomon - Academia.edu PDF) External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement | Anne Vincent-salomon - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/86436036/mini_magick20220524-18718-tg1b1v.png?1653457246)
PDF) External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement | Anne Vincent-salomon - Academia.edu
![Cancers | Free Full-Text | Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review Cancers | Free Full-Text | Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review](https://pub.mdpi-res.com/cancers/cancers-14-01898/article_deploy/html/images/cancers-14-01898-g001-550.jpg?1649669854)
Cancers | Free Full-Text | Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
![Adjuvant! Online is overoptimistic in predicting survival of Asian breast cancer patients - ScienceDirect Adjuvant! Online is overoptimistic in predicting survival of Asian breast cancer patients - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804912000986-gr2.jpg)
Adjuvant! Online is overoptimistic in predicting survival of Asian breast cancer patients - ScienceDirect
![Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial | Journal of Clinical Oncology Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2019/jco.2019.37.issue-26/jco.19.00647/20190827/images/large/jco.19.00647ta1.jpeg)
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial | Journal of Clinical Oncology
![Cancers | Free Full-Text | A Comparison between the Online Prognostic Tool PREDICT and myBeST for Women with Breast Cancer in Malaysia Cancers | Free Full-Text | A Comparison between the Online Prognostic Tool PREDICT and myBeST for Women with Breast Cancer in Malaysia](https://www.mdpi.com/cancers/cancers-15-02064/article_deploy/html/images/cancers-15-02064-g001.png)
Cancers | Free Full-Text | A Comparison between the Online Prognostic Tool PREDICT and myBeST for Women with Breast Cancer in Malaysia
![Adjuvant Treatment for Older Women with Invasive Breast Cancer - Trevor A Jolly, Grant R Williams, Sita Bushan, Mackenzi Pergolotti, Kirsten A Nyrop, Ellen L Jones, Hyman B Muss, 2016 Adjuvant Treatment for Older Women with Invasive Breast Cancer - Trevor A Jolly, Grant R Williams, Sita Bushan, Mackenzi Pergolotti, Kirsten A Nyrop, Ellen L Jones, Hyman B Muss, 2016](https://journals.sagepub.com/cms/10.2217/whe.15.92/asset/images/large/10.2217_whe.15.92-fig2.jpeg)